I really don't want to be a doctor

Chapter 110 Received
"Mr. Duckman, the latest batch of papers has been compiled." The editor of the magazine stood in front of Duckman's desk and said, "I have sent the most recently submitted papers from all over the world to your mailbox."

In addition to the editor-in-chief, the magazine also has many other editors. They are subordinate to each editor-in-chief and are mainly responsible for the preliminary review of papers.

"Oh, okay." Duckman was working on a study on a new drug. "Any special papers out there recently?"

"Mr. Duckman, according to the results of the current expert reviews, no breakthrough research papers have been found yet." The editor thought for a while, and then browsed through the expert review results, "But..."

"Oh, but what?" Duckman pushed his glasses and looked up at his little editor.

This little editor's eyesight is not bad, but the professional level is not enough and needs to be honed for a while.

"Here is a paper. The result of the expert review is that the idea is novel, but the expert questioned the authenticity of the article and asked the author to make supplementary experimental explanations." The editor carefully read the document in his hand.

"Which country is the author from?" Duckman asked.

"Huaxia."

"Hehe." Duckman suddenly realized, no wonder he questioned the authenticity of the article.

Chinese scholars are notorious for falsifying papers in the world. Many SCI journals have even been removed from the SCI directory because of the continuous "watering" of Chinese scholars.

Therefore, many international journals will raise the review standards of Chinese scholars' papers, and even reject the papers of Chinese scholars.

"Which school is the author from?" Duckman continued.

"Wait, let me take a look." The editor clicked on the mailbox again, "It seems to be Ning... Ning'an Medical College, a small school that I have never heard of."

"Ning'an?" Duckman asked puzzled, "Sounds familiar, which city in China?"

"Fancheng in China."

"Fancheng...the only university in Fancheng I know is Fancheng Medical University, this Ning'an Medical College..." Duckman felt like he had heard the name somewhere, but couldn't remember it for a while.

"Mr. Duckman, I checked, this is a second-rate medical school in China." The editor said, "Do you still need to read this paper?"

"Thank you." Darkman nodded, "I'll take a look when I have free time."

The little editor immediately understood that when Duckman said this, he usually would not read this article again.

"Sir, I'll go back to work first."

"Go."

Darkman continues to work on his thesis on anticancer drugs.

After a while, a name suddenly flashed in my mind, and this name was suddenly associated with Ning'an Medical College.

Darkman quickly opened the computer browser and entered the name "Wu Qiming" in the search engine.

"Wu Qiming, a scientist of Chinese descent, an academician of the National Academy of Sciences... graduated from Huaxia Ning'an Medical College."

"No wonder, I think the name of this college is very familiar. It turns out that Wu Qiming, an academician of the National Academy of Sciences, graduated from this school."

Also in the field of pharmacology, Dachman is very familiar with top international experts, and even has some research on the lives of these people.

Wu Qiming can be regarded as a figure at the top of the pyramid in the field of pharmacology, and Duckman has dealt with him many times.

Dachman thought for a while, then opened the mailbox, and clicked on this paper from Ning'an Medical College.

"A new type of anticoagulant?"

As soon as he saw the name of the paper, Duckman became interested. According to him, there are companies in the United States currently researching new anticoagulant drugs, but they are still in the phase I clinical trial stage.

"New anticoagulant drugs do not act on multiple coagulation factors like traditional anticoagulant drugs such as warfarin, but only inhibit a certain coagulation factor, and the two most important targets in the coagulation cascade are Xa and IIa respectively. "

The more Duckman reads, the more interesting the idea of ​​this paper is. A lot of basic research has been done in the paper, and the arguments are sufficient. It is definitely not the case of "poor authenticity" given by expert reviewers.

"This type of drug is aimed at a single active coagulation factor. The anticoagulant effect does not depend on antithrombin. It takes effect orally and has a shorter half-life compared with warfarin. It has a good dose-effect relationship and is compatible with food and drugs. There is little interaction between them, oral use does not need to monitor routine blood coagulation indicators, and can reduce or avoid drug efficacy decline or bleeding adverse events caused by improper medication, and the individual differences in dosage are small and only need to be taken at a fixed dosage.

……

After quickly browsing through the paper, Dachman's intuition told him that if the drug has really been developed, the future profits will be immeasurable.

This new type of anticoagulant is different from the traditional anticoagulant in that it does not require frequent blood coagulation measurements, and food and drugs have little effect on its efficacy, and the probability of causing bleeding is similar to that of conventional anticoagulants.

This drug will definitely slowly replace today's conventional anticoagulants.

"My God, this is really a beautiful paper!" Duckman exclaimed. "It must have been written by an old professor at Ning'an Medical College."

In addition to the rigorous scientific arguments, the writing level of his English papers is not as rough as that of ordinary Chinese scholars, it seems fluent, and there are even some gorgeous words.

Dachman carefully studied this paper again, then found the mailbox in the article, thought about it and started writing a manuscript for the author to reply.

……

The library of Ning'an Medical College, the electronic reading room on the fourth floor.

"Ding dong."

Jing Xiaoran was preparing to open a literature to continue research on "New Oral Anticoagulants", when suddenly the computer sounded the sound.

A line of small words appeared in the lower right corner of the computer, "You have a new email, please check it carefully."

"Is it spam again?"

Jing Xiaoran casually clicked on the mailbox, and a series of English letters appeared in front of his eyes.

"congratulations...your article is accepted..."

"No." Jing Xiaoran thought, "It's not junk mail!"

He quickly scanned the contents of the email.

"It's actually a reply email from the magazine!"

Jing Xiaoran concentrated and read the email carefully from beginning to end.

half an hour.

"The manuscript has been accepted!" Jing Xiaoran's face brightened, "And I didn't ask for further revisions. It will be published in half a month. Is it so fast?"

To know the speed at which general papers appear in publications, half a year to two years is normal.

It is rare to see the magazine in half a month!

Hong Sheng, who was sitting on the side, also noticed Jing Xiaoran's abnormality at this moment.

"Squad leader, what's wrong with you?" Hong Sheng leaned over and asked softly.

He looked at Jing Xiao Ran's computer screen, and it was all in English, who could understand it?

"I submitted a paper recently, and I just received a reply from the magazine, and it was accepted." Jing Xiaoran suppressed his inner joy, and said softly.

Although Hong Sheng is not interested in these academic matters, he also knows how difficult it is for undergraduates to publish articles.

"So amazing!" Hong Sheng exclaimed in surprise, "Which magazine?"

"American "DRUG DISCOVERY TODAY" magazine." Jing Xiaoran said.

"For foreign journals, shouldn't they be all English papers?"

"Ah."

"Squad leader, you are amazing!" Hong Sheng gave a thumbs up.

At the same time, he silently recited the name of the magazine in his heart.

"DRUG DISCOVERY TODAY."

He was embarrassed to ask the level of this magazine, thinking about checking it out by himself later.

(End of this chapter)